Biotest Pharmaceuticals Corporation

Quick facts

Phase 3 pipeline

• Civacir® 10% · Immunology / Infectious Disease
  Civacir is a hepatitis C immunoglobulin (HCV-IG) that provides passive immunity by supplying antibodies against hepatitis C virus to prevent reinfection in transplant recipients.

Phase 1 pipeline

• BT062
• BT062 , intravenous administration

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Biotest Pharmaceuticals Corporation portfolio CI brief
• Biotest Pharmaceuticals Corporation pipeline updates RSS